Posted inComunicati
PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE IRVINE, Calif., May 28, 2026 /PRNewswire/ -- PeproMene Bio, Inc.…









